In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 3, 1997, Pages 1433-1444

  Panek, Robert L ^a   Lu, Gina H ^a   Klutchko, Sylvester R ^a   Batley, Brian L ^a   Dahring, Tawny K ^a   Hamby, James M ^a   Hallak, Hussein ^a   Doherty, Annette M ^a   Keiser, Joan A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE; PD 166285; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VITRONECTIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; DRUG DETERMINATION; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; DNA; ENZYME INHIBITORS; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; PYRIDONES; PYRIMIDINES; RABBITS; RATS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SPODOPTERA; TYROSINE;

EID: 0031471249     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. ALONSO, G., KOEGL, M., MAZURENKO, N. AND COURTNEIDGE, S. A.: Sequence requirements for binding of src family tyrosine kinases to activated growth factor receptors. J. Biol. Chem. 270: 9840-9848, 1995.
2. ANGEL, P., IMAGAWA, M., CHIU, R., STEIN, B., IMBRA, R. J., RHAMSDORF, H. J., JONAT, C., HERRLICH, P. AND KARIN, M.: Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49: 729-739, 1987.
3. ANTONIADES, H. N., GALANOPOULOS, T., NEVILLE-GOLDEN, J. AND O'HARA, C. J.: Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc. Natl. Acad. Sci. U.S.A. 89: 3942-3946, 1992.
4. BILDER, G. E., KRAWIEC, J. A., MCVETY, K., GAZIT, A., GILON, C., LYALL, R., ZILBERSTEIN, A., LEVITZKI, A., PERRONE, M. H. AND SCHREIBER, A. B.: Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am. J. Physiol. 260: C721-C730, 1991.
5. BLANKLEY, C. J., BOSCHELLI, D. H., DOHERTY, A. M., HAMBY, J. M., KLUTCHKO, S. AND PANEK, R. L.: Pyrido [2,3-D] pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. United States Patent 5,620,981. 1997.
6. BLYSTONE, S. D., LINDBERG, F. P., WILLIAMS M. P. MCHUGH, K. P. AND BROWN, E. J.: Inducible tyrosine phosphorylation of the β3 integrin requires the αv integrin cytoplasmic tail. J. Biol. Chem. 271: 31458-31462, 1996.
7. BRIDGES, A. J., ZHOU, H., CODY, D. R., REWCASTLE, G. W., MCMICHAEL, A., SHOWALTER, H. D., FRY, D. W., KRAKER, A. J. AND DENNY, W. A:. Tyrosine kinase inhibitors: unusually steep structure-activity relationship for analogs of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 39: 267-276, 1996.
8. BUCHDUNGER, E., ZIMMERMANN, J., METT, H., MEYER, T., MULLER, M., REGENASS, U. AND LYDON, N.: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U.S.A. 92: 2258-2262, 1995.
9. BURKE, T. R.: Protein-tyrosine kinase inhibitors. Drugs Future 17: 119-131, 1992.
10. CADENA, D. L. AND GILL, G. N.: Receptor tyrosine kinases. FASEB J. 6: 2332-2337, 1992.
11. CHEN, Q., KINCH, M. S., LIN, T. H., BURRIDGE, K. AND JULIANO, R. L.: Integrin mediated cell adhesion activates mitogen-activated protein kinases. J. Biol. Chem. 2697: 26602-26605, 1994.
12. CLAESSON-WELSH, L.: Platelet-derived growth factor receptor signals. J. Biol. Chem. 269: 32023-32026, 1994.
13. CLELAND, W. W.: Statistical analysis of enzyme kinetic data. Methods Enzymol. 63: 103-112, 1979.
14. 125FAK. Mol. Cell. Biol. 14: 147-155, 1994.
15. CONNOLLY, C., HAMBY, J., SCHROEDER, M., PANEK, R., LU, G., AMAR, A., SHEN, C., KRAKER, A., FRY, D. AND DOHERTY, A.: Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg. and Med. Chem. Let., in press, 1997.
16. DAHRING, T. K., LU, G. H., HAMBY, J. M., BATLEY, B. L., KRAKER, A. J. AND PANEK, R. L.: Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 281: 1446-1456, 1997.
17. DOLLE, R. E., DUNN, J. A., BOBKO, M., SINGH, B., KUSTER, J. E., BAIZMAN, E., HARRIS, A. L., SAWUTZ, D. G., MILLER, D., WANG, S., FALTYNEK, C. R., XIE, W., SARUP, J., BODE, D. C., PAGANI, E. D. AND SILVER, P. J.: 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular β-type platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 37: 2627-2629, 1994.
18. ELDER, J. T., FISHER, G. J., LINDQUIST P. B., BENNET, G. L., PITTELKOW, M. R., COFFEY, R. J., ELLINGSWORTH, L., DERYNCK, R. AND VOORHEES, J. J.: Overexpression of transforming growth factor a in psoriatic epidermis. Science 243: 811-814, 1989.
19. FALTYNEK, C. R., WANG, S., MILLER, D., MAUVAIS, P., GAUVIN, B., REID, J., XIE, W., HOEKSTRA, S., JUNIEWICZ, P., LEHR, R., SAWUTZ, D. G. AND MURPHY, D.: Inhibition of T lymphocyte activation by a novel p56lck tyrosine kinase inhibitor. J. Enzyme Inhib. 9: 111-122, 1995.
20. FABUNMI, R. P., BAKER, A. H., MURRAY, E. J., BOOTH, R. F. G. AND NEWBY, A. C.: Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem. J. 315: 335-342, 1996.
21. FANTL, W., JOHNSON, D. E. AND WILLIAMS, L. T.: Signalling by receptor tyrosine kinases. Annu. Rev. Biochem. 62: 453-481, 1993.
22. FINI, M. E., BARTLETT, J. D., MATSUBARA, M., RINEHART, W. B., MODY, M. K., GIRARD, M. T. AND RAINVELLE, M.: The rabbit gene for 92-kDa matrix metalloproteinase: role of AP1and AP2 in cell type-specific transcription. J. Biol. Chem. 269: 28620-28628, 1994.
23. FRIESEL, R. E. AND MACIAG, T.: Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. FASEB J. 9: 919-925, 1995.
24. FRY, D. W., KRAKER, A. J., CONNORS, R. C., ELLIOTT, W. L., NELSON, J. M., SHOWALTER, H. D. H. AND LEOPOLD, W. R.: Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anti-Cancer Drug Design 9: 331-351, 1994a.
25. FRY, D. W., KRAKER, A. J., MCMICHAEL, A., AMBROSO, L. A., NELSON, J. M., LEOPOLD, W. R., CONNORS, R. W. AND BRIDGES, A. J.: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265: 1093-1095, 1994b.
26. GAZIT, A., YAISH, P., GILON, C. AND LEVITZKI, A.: Tyrphostins 1. Synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 32: 2344-2352, 1989.
27. HAJJAR, D. P. AND POMERANTZ, K. B.: Signal transduction in atherosclerosis: integration of cytokines and the eicosanoid network. FASEB J. 6: 2933-2941, 1992.
28. HANKS, S. K., QUINN, A. M., HUNTER, T.: The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 241: 42-52, 1988.
29. HANSEN, K., JOHNELL, M., SIEGBAHN, A., RORSMAN, C., ENGSTRÖM, U., WERNSTEDT, C., HELDIN, C.-H. AND RÖNNSTRAND, L.: Mutation of a Src phosphorylation site in the PDGF β-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. EMBO J. 15: 5299-5313, 1996.
30. HYNES, R. O.: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25, 1992.
31. HYNES, N. E. AND TERN, D. F.: The biology of the erB2/neu/HER-2 and its role in cancer. Biochem. Biophys. Acta 1198: 165-184, 1994.
32. JAYE, M., SCHLESSINGER, J. AND DIONNE, C. A.: Fibroblast growth factor receptor tyrosine kinases: Molecular analysis and signal transduction. Biochem. Biophys. Acta 1135: 185-199, 1992.
33. JENSEN, R. A., BEELER, J. F., HEIDARAN, M. A. AND LAROCHELLE, W. J.: Characterization of baculovirus-expressed human α and β platelet-derived growth factor receptors. Biochemistry 31: 10887-10892, 1992.
34. KLOHS, W., STEINKAMPF, R., DRISCOLL, D., KLUTCHKO, S., HAMEY, J., LU, G., VINCENT, P., ROBERTS, B. AND ELLIOT, W.: Characterization of PDGF tyrosine kinase inhibitors in in vitro and in vivo tumors. Am. Soc. Cancer Res 38: 632, 1997.
35. KRAKER, A. J., MOORE, C. W., AMAR, A. M., SHEN, C. S., NELSON, J., SLINTAK, V., FRY, D. W., LU, G., PANEK, R., BARVIAN, M., KLUTCHKO, S. AND HAMBY, J.: Cytotoxicity and phospho-tyrosine effects of c-Src kinase inhibition by substituted pyridopyrimidine tyrosine kinase inhibitors in human colon carcinoma cell lines. Am. Soc. Cancer Res. 38: 633, 1997.
36. KYPTA, R. M., GOLDBERG, Y., ULUG, E. T. AND COURTNEIDGE, S. A.: Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell 62: 481-492, 1990.
37. LEATHERBARROW, R. J.: GraFit User's Guide, Version 3.0. Erithacus Software Ltd., Staines, UK, 1992.
38. LIAW, L., LINDNER, V., SCHWARTZ, S. M., CHAMBERS, A. F., GIACHELLI, C. M.: Osteopontin and β3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Arg-dependent endothelial migration in vitro. Circ. Res. 77: 665-672, 1995.
39. LIBBY, P., SCHWARTZ, D., BROGI, E., TANAKA, H. AND CLINTON S. K.: A cascade model for restenosis: A special case of atherosclerosis progression. Circulation. 86: 47-52, 1992.
40. LYALL, R. M., ZILBERSTEIN, A., GAZIT, A., GILON, C., LEVITZKI, A. AND SCHLESSINGER, J.: Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J. Biol. Chem. 264: 14503-14509, 1989.
41. OGAWARA, H., AKIYAMA, T. AND WATANABE, S.-I.: Inhibition of tyrosine protein kinase activity by synthetic isoflavones and flavones. J. Antibiot. 42: 340-343, 1988.
42. ONODA, T., ISHIKI, K., TAKEUCHI, T., TATSUTA, K. AND UMEZAWA, K.: Inhibition of tyrosine kinase and epidermal growth factor receptor internalization by lavendustin: A methyl ester in cultured A431 cells. Drugs Exp. Clin. Res. 16: (6) 249-253, 1990.
43. PANAYOTOU, G. AND WATERFIELD, M. D.: The assembly of signaling complexes by receptor tyrosine kinases. Bioessays 15: 171-177, 1993.
44. PARSONS, J. T.: Integrin-mediated signalling: Regulation by protein tyrosine kinases and small GTP-binding proteins. Curr. Opin. Cell. Biol. 8: 146-152, 1996.
45. PEREZ, R., BETSHOLTZ, C., WESTERMARK, B. AND HELDIN C. H.: Frequent expression of growth factors of mesenchymal cells in human mammary carcinoma cell lines. Cancer Res. 47: 3425-3429, 1987.
46. ROSS, R.: Platelet derived growth factor. Landet 1: 1179-1182, 1989.
47. ROSS, R.: The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J. Cell Biol. 50: 172-186, 1971.
48. SAWUTZ, D. G., BODE, D. C., BRIGGS, G. M., REID, J. R., CANNIFF, P., CALDWELL, L., FALTYNEK, C. R., MILLER, D., DUNN, J. A., DEGARAVILLA, L., GUILES, J. W., WEIGELT, C., MICHNE, W., TREASURYWALA, A. M. AND SILVER, P. J.: In vitro characterization of a novel series of platelet derived growth factor receptor tyrosine kinase inhibitors. Biochem. Pharmacol. 51: 1631-1638, 1996.
49. SCHWARTZ, R. S., HOLMES, D. R. AND TOPOL, E. J.: The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 20: 1284-1293, 1992.
50. SCHWARTZ, S. M., DEBLOIS, D. AND O'BRIAN, E. R. M.: The intima: Soil for atherosclerosis and restenosis. Circ. Res. 77: 445-465, 1995.
51. SHOWALTER, H. D. H., KLUTCHKO, S., BOSCHELLI, D., BARVIAN, M. R., HAMBY, J., SCHROEDER, M., TRUMPP-KALLMEYER, S., KRAKER, A. J., LU, G., MOORE, C. W. AND DOHERTY, A. M.: The development of substituted 2-anilinopyridi [2,3-d] pyrimidines as novel, potent inhibitors of the c-Src tyrosine kinase. Am. Soc. Cancer Res. 38: 470, 1997.
52. SITARAS, N. M., SARIBAN, E., BRAVO, M., PANTAZIS, P. AND ANTONIADES, H. N.: Constitutive production of platelet-derived growth factor like proteins by human prostate carcinoma cell lines. Cancer Res. 48: 1930-1935, 1988.
53. THOMPSON, A. M., FRY, D. W., KRAKER, A. J. AND DENNY, W. A.: Tyrosine kinase inhibitors. 2. Synthesis of 2,2′-dithiobis(1H-indole-3-alkanmides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60v-src protein tyrosine kinases. J. Med. Chem. 37: 598-608, 1994.
54. TRAXLER, P. AND LYDON, N.: Recent advances in protein tyrosine kinase inhibitors. Drugs Future 20: 1261-1274, 1995.
55. TRAXLER, P. M., FURET, P., METT, H., BUCHDUNGER, E., MEYER, T. AND LYDON, N.: 4-(Phenylamino)pyrrolopyrimidines: Potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 39: 2285-2292, 1996.
56. TRINKS, U., BUCHDUNGER, E. AND FURET, P.: Dianilinopthalimides: Potent and selective, ATP competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 37: 1015-1027, 1994.
57. ULLRICH, A. AND SCHLESSINGER, J.: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
58. WARD, W. H. J., COOK, P. N., SLATER, A. M., DAVIES, H., HOLDGATE, G. A. AND GREEN, L. R.: Epidermal growth factor receptor tyrosine kinase: Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 48: 659-666, 1994.
59. WILHELM, S. M., COLLIER, I. E., MARMER, B. L., EISEN, A. Z., GRANT, G. A. AND GOLDBERG, G. I.: SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 264: 17213-17221, 1989.
60. ZIMMERMANN, J., BUCHDUNGER, E., METT, H., MEYER, T., LYDON, N. B. AND TRAXLER, P.: Phenylamino-pyrimidine (PAP)-derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. 6: 1221-1226, 1996.